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nmol/L, N 5 30, P , 0.05) with normal renal function andSerum C-peptide concentrations poorly phenotype type 2 dia-
were indistinguishable between type 1 and type 2 diabetics.betic end-stage renal disease patients.
Although 10% of the diabetic ESRD study population wasBackground. A homogeneous patient population is neces-
classified as type 1 diabetics using clinical criteria, only 1.5%sary to identify genetic factors that regulate complex disease
of these patients had C-peptide levels less than 0.20 nmol/L,pathogenesis. In this study, we evaluated clinical and biochemi-
the standard cut-off used to discriminate type 1 from type 2cal phenotyping criteria for type 2 diabetes in end-stage renal
diabetes in patients with normal renal function. However, thedisease (ESRD) probands of families in which nephropathy
criteria of C-peptide concentrations .0.50 nmol/L and diabetesis clustered. C-peptide concentrations accurately discriminate
onset in patients who are more than 38 years old identify typetype 1 from type 2 diabetic patients with normal renal function,
2 diabetes with a 97% positive predictive value in our ESRDbut have not been extensively evaluated in ESRD patients. We
population.hypothesized that C-peptide concentrations may not accurately
Conclusions. Accepted clinical criteria, used to discriminatereflect insulin synthesis in ESRD subjects, since the kidney
type 1 and type 2 diabetes, failed to classify a significant propor-is the major site of C-peptide catabolism and would poorly
tion of diabetic ESRD patients. In contrast to previous reports,correlate with accepted clinical criteria used to classify diabetics
C-peptide levels were elevated in the majority of type 1 ESRDas types 1 and 2.
diabetic patients and did not improve the power of clinicalMethods. Consenting diabetic ESRD patients (N 5 341)
parameters to separate them from type 2 diabetic or nondia-from northeastern Ohio were enrolled. Clinical history was
betic ESRD subjects. Accurate classification of diabetic ESRDobtained by questionnaire, and predialysis blood samples were
patients for genetic epidemiological studies requires both clini-collected for C-peptide levels from subjects with at least one
cal and biochemical criteria, which may differ from norms usedliving diabetic sibling (N 5 127, 48% males, 59% African
in diabetic populations with normal renal function.Americans).
Results. Using clinical criteria, 79% of the study population
were categorized as type 1 (10%) or type 2 diabetics (69%),
while 21% of diabetic ESRD patients could not be classified. Classification of diabetics as type 1 (very low or absent
In contrast, 98% of the patients were classified as type 2 diabet-
endogenous insulin secretion) or type 2 (significant pan-ics when stratified by C-peptide concentrations using criteria
creatic insulin production with peripheral insulin resis-derived from the Diabetes Control and Complications Trial
tance) remains imprecise, although large, well-designedResearch Group (DCCT) and UREMIDIAB studies. Catego-
rization was concordant in only 70% of ESRD probands when studies have validated both clinical and biochemical cri-
C-peptide concentration and clinical classification algorithms teria in non-end-stage renal disease (ESRD) patients
were compared. Using clinical phenotyping criteria as the stan- [1–4]. Intermediate diabetic phenotypes have recentlydard for comparison, C-peptide concentrations classified dia-
been recognized, further complicating categorization.betic ESRD patients with 100% sensitivity, but only 5% speci-
For example, 10 to 15% of subjects with clinical featuresficity. The mean C-peptide concentrations were similar in
diabetic ESRD patients (3.2 6 1.9 nmol/L) and nondiabetic suggestive of type 2 diabetes have slowly progressive,
ESRD subjects (3.5 6 1.7 nmol/L, N 5 30, P 5 NS), but late onset, autoimmune injury to pancreatic b cells [5, 6],
were 2.5-fold higher compared with diabetic siblings (1.3 6 0.7 which results in a lack of insulin production. Conversely,
some patients with idiopathic type 1 diabetes do not
have an autoimmune disorder [7].Key words: genetic epidemiology, IDDM, NIDDM, heredity, insulin
secretion, progressive renal injury, classifying diabetics. Classification of diabetes is important for several rea-
sons. First, appropriate categorization can guide therapyReceived for publication February 18, 2000
for diabetic patients since insulin treatment in some typeand in revised form April 28, 2000
Accepted for publication May 8, 2000 2 patients may result in hyperinsulinemia with adverse
effects [8]. In addition, novel, mechanism-based thera-Ó 2000 by the International Society of Nephrology
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Table 1. Classification criteriapies for diabetes have been developed, such as immuno-
modulators and antiviral agents for type 1 diabetics Type 1 diabetes
1. Age of onset ,25 years [21, 29, 30] and one of the following[9–11] or troglitazone for type 2 diabetics [12]. Second,
criteria:imprecise classification of diabetes has generated con- a. History of diabetic ketoacidosis [21, 29, 30, 33];
flicting, epidemiological descriptions of diabetic ne- b. Treatment with insulin only and/or insulin therapy initiated
less than one year after diabetes diagnosis [21, 29, 33];phropathy. In the past, some authors have suggested that
c. Weight at diagnosis and/or maximal weight ,105% of the idealtype 1 diabetics had an increased chance of developing body weight [21, 27, 29, 30].
ESRD [13], whereas more recent studies demonstrated Type 2 diabetes
1. Onset of diabetes after 40 years of age [2, 21, 30, 31], no historya similar risk for nephropathy in both type 1 and type
of diabetic ketoacidosis [4, 29], and one of these additional criteria:2 diabetics [14]. Finally, accurate phenotypes are critical a. Weight at diagnosis and/or maximum weight .115% of ideal
for identifying chromosomal loci, which contain genes body weight [21, 28–30];
b. No consistent insulin therapy during the first two years afterthat cause complex diseases [15]. Although genetic fac-
diabetes diagnosis [21, 29, 31].tors regulate, in part, diabetic nephropathy pathogenesis 2. Both (1a) and (1b) if diabetes onset occurred between 30 and 40
[recently reviewed in 16–18], reports of nephropathy sus- years [34].
Unclassified diabetics: patients not categorized by the above criteriaceptibility loci have been conflicting and not replicated
in different patient populations. Incomplete phenotyp-
ing, as well as study design (for example, case control
vs. sibling pair), undoubtedly increased heterogeneity
least one living diabetic sibling have been phenotypedwithin the study populations [17–20] and has confounded
and genotyped. To phenotype these patients, the follow-reproducible identification of diabetic nephropathy loci.
ing information was obtained: age, age at diabetes onset,Molecular mechanisms of type 1 and type 2 diabetes are
age at dialysis initiation, duration of kidney disease,different, suggesting that different genetic pathways may
weight and height at 18 years of age and at the time ofregulate nephropathy susceptibility in type 1 and type 2
the interview, maximum weight during life, onset anddiabetics independently. As a result, accurate classifica-
duration of diabetes treatment with diet and/or oral hy-tion of type 1 versus type 2 diabetic ESRD patients
poglycemic drugs and/or insulin, history of diabeticshould improve the likelihood of identifying diabetic ne-
coma, and/or diabetic ketoacidosis (DKA). Medical re-phropathy genes.
cords, when available, were used to confirm the interviewWe are currently conducting a large multicenter study,
data. Simultaneous serum glucose and C-peptide levelsusing a family based strategy, to identify susceptibility
were determined for each patient from blood samplesgenes for type 2 diabetic nephropathy. In other reports,
obtained at the beginning of a dialysis treatment (dis-C-peptide concentrations combined with clinical criteria
cussed later in this article). Body mass index was calcu-have been used to identify type 2 diabetics, with and
lated as patient weight (in kilograms) divided by thewithout ESRD [1, 2, 21]. However, the value of C-pep-
square of patient height (in meters). The Institutionaltide concentrations in classifying diabetic ESRD patients
Review Boards of the MetroHealth System, Universityhas not been extensively evaluated. Since the kidney is
Hospitals of Cleveland, and the Cleveland Clinic Foun-the major site for C-peptide catabolism and excretion
dation approved this protocol.[22–26], we hypothesized that C-peptide concentrations
may not improve the power of clinical criteria to catego-
Clinical diabetic phenotyping criteriarize ESRD patients, in contrast to patients with normal
We developed clinical criteria to classify ESRD pa-renal function, as type 1 and type 2 diabetics.
tients as type 1 or type 2 diabetics using the following
reports: (1) WHO and American Diabetes Association
METHODS 1997 guidelines [27, 28], (2) studies of diabetic ESRD
Study population patients (Michigan Kidney Registry [29] and UREMID-
IAB Study [30]), (3) studies of diabetics with normalThe study population was selected from prevalent
[2, 31] and abnormal glomerular filtration rate (GFR)ESRD patients in eight hemodialysis units in metro-
[21] who were phenotyped using clinical parameters andpolitan Cleveland (OH, USA). From the population
C-peptide concentrations, and (4) studies of genetic sus-screened (N 5 1237), 915 completed a screening ques-
ceptibility for type 2 diabetes [1, 17, 32]. Table 1 liststionnaire to obtain medical history and family history
the criteria we used to classify enrolled ESRD patientsof renal disease. Of these, 341 patients (37.3%) had a
as type 1 or 2 diabetics.diagnosis of diabetes on their Health Care Financing
Administration (HCFA) 2728 forms and a long-standing
Serum glucose and C-peptide assayshistory of diabetes therapy with diet, insulin, and/or oral
The Core Laboratory of the General Clinical Researchhypoglycemic agents. From this group, 127 ESRD pa-
tients (13.9%) with a family history of diabetes and at Center of Case Western Reserve University measured
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Fig. 1. An algorithm to classify diabetes ac-
cording to C-peptide concentrations. As de-
scribed in the Methods section, C-peptide con-
centrations were assayed in a serum sample
obtained at the initiation of dialysis, and dia-
betes was classified as type 1 or type 2. C-pep-
tide concentrations are expressed as nmol/L.
Prior to classification, serum C-peptide levels
were repeated after overnight fasting and Sus-
tacal stimulation in study participants, who
had random C-peptide concentrations ,0.5
nmol/L and diabetes onset prior to an age of
30, or in subjects of any age with C-peptide
concentrations ,0.2 nmol/L. No additional
tests were obtained in study participants, who
had serum C-peptide concentrations .0.5
nmol/L or in subjects with C-peptide concen-
trations from 0.2 to 0.5 nmol/L but in whom
diabetes onset occurred after 30 years of age.
Abbreviations are: [C-peptide], C-peptide con-
centrations; DM, diabetes mellitus; years, years
of age.
serum glucose and C-peptide concentrations. Glucose was long after apparent disease onset in type 2 diabetics [35],
assayed using glucose-oxidase, and C-peptide concentra- we obtained predialysis blood samples (at 7 a.m. for first
tions were determined using a standard double-antibody shift, 12 p.m. for second shift, and 4 p.m. for third shift
radioimmunoassay (Diagnostic Products Corporation, subjects) for serum glucose and C-peptide concentra-
Los Angeles, CA, USA). For C-peptide determinations, tions. Diabetic ESRD patients were classified as type 1 or
blood was collected by venipuncture in serum separator type 2 diabetics according their C-peptide concentrations
(red-gray top, no anticoagulant) tubes, and the cells were using the Diabetes Control and Complications Trial Re-
separated by centrifugation. Standard concentrations of search Group (DCCT) algorithm [2] with the following
serum-based, human C-peptide, and patient sera were modifications:
mixed with [125I]C-peptide and rabbit anti–C-peptide anti-
Pre-HD C-peptide .0.50 nmol/L. These diabetic ESRDserum for four hours at room temperature. A precipitat-
patients were classified as type 2 diabetics without aing solution, containing goat anti-rabbit g-globulin and
Sustacal-stimulation test since in the DCCT study, onlypolyethylene glycol, was used to separate bound from
type 2 diabetics had basal or stimulated C-peptide con-free [125I]C-peptide. The antibody-bound fraction was
centrations .0.50 nmol/L (Fig. 1).precipitated and counted in a g-counter. Patient sample
Pre-HD C-peptide value between 0.20 nmol/L and 0.50concentrations were determined from a calibration
nmol/L. Using DCCT criteria [2], a Sustacal stimulationcurve, generated from the standards. Coefficients of vari-
test was performed if diabetes onset occurred beforeation for intra-assay and interassay variability were 3.9 6
1.1% and 4.7 6 2.4%, respectively. The assay detection the age of 30 (Fig. 1). ESRD patients with Sustacal-
limit was approximately 0.07 nmol/L. stimulated C-peptide concentrations .0.50 nmol/L were
classified as type 2 diabetics. Patients with stimulated
Sustacal-stimulated C-peptide concentrations C-peptide concentrations ,0.50 nmol/L were classified
After an eight-hour fast (from midnight), baseline glu- as type 1 diabetics. If diabetes onset was after 30 years
cose and C-peptide concentrations were determined. of age, patients were categorized as type 2 diabetics
Sustacal (6 cc/kg, maximum 360 cc) was then adminis- without performing a Sustacal-stimulation test [2].
tered orally over 10 minutes. After 90 minutes, samples Pre-HD C-peptide value ,0.20 nmol/L. Sustacal-stim-
for stimulated glucose and C-peptide measurements
ulation tests were performed in all patients with pre-were obtained.
hemodialysis C-peptide concentrations ,0.20 nmol/L
(0.6 ng/L; Fig. 1). If stimulated C-peptide concentrationsC-peptide phenotyping criteria
remained ,0.20 nmol/L, subjects were considered typeIn contrast to most published studies, which measure
1 diabetics regardless of age of diabetes onset. Patientsbasal and post-stimulation C-peptide concentrations to
were classified as type 2 diabetics if the age of diabetesdocument absence of endogenous insulin production
onset was after the patient was 30 years of age, and the[1, 2], our goal was to identify patients with type 2 diabe-
tes (Fig. 1). Since insulin synthesis is maintained, even stimulated C-peptide concentrations were .0.20 nmol/L.
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Table 2. Clinical characteristics and C-peptide levels of the study population (N 5 127)
Lower Upper
Parameter Mean SD Minimum quartile Median quartile Maximum
Age years 61.9 10.1 39 54 64 70.2 84
Age at diabetes onset years 41.3 12.7 10 33 40 50.0 82
Diabetes duration years 20.6 9.4 2 14.3 20.0 28.0 43.0
Pre-HD [CP] nmol/L 3.22 1.85 0.19 2.07 2.83 4.24 8.81
Abbreviations are: HD, hemodialysis; [CP], C-peptide concentration.
Table 3. Comparison between patients treated with insulinIf diabetes onset appeared when patients were less than
at the time of the study and those on diet and/or oral
30 years of age, they were classified as type 1 diabetics hypoglycemic agents
if stimulated C-peptide concentrations were $20 nmol/L
Current therapy for diabetesbut $0.50 nmol/L, and patients were classified as type
Diet and/or oral2 diabetics if the stimulated C-peptide levels were .0.50
hypoglycemic
nmol/L. Insulin agents
(N 5 79) (N 5 48) P
Statistics
% Males 20.3 64.5 ,0.05
% African Americans 55.7 62.5 NSAll analyses were performed using a C-STATt pack-
Insulin treatment atage (Oxford Statistics, UK). Intergroup differences be-
diagnosis
tween continuous variables were assessed by two-tailed, % of patients 45.6 18.8 ,0.05
Diabetes phenotypea NSnonpaired t-tests and analysis of variance (ANOVA;
Type 1 12 1multiple comparisons). Significant differences in propor-
Type 2 49 39
tions were assessed by chi-square test. P , 0.05 was Type unknown 18 9
Pre-HD [CP] nmol/L 2.9061.78 3.7461.86 ,0.05considered to be significant.
[Glucose] mg/dL 196.36100.1 129.8670.9 ,0.05
Age at diagnosis years 39.0612.1 44.9613.1 ,0.05
Diabetes duration years 21.6619.3 19.069.3 NSRESULTS
BMI at 18 years kg/m2 26.868.6 25.867.0 NS
Maximum BMI kg/m2 38.1610.6 36.368.5 NSStudy population demographics
Current BMI kg/m2 30.968.2 26.964.9 ,0.05
One hundred twenty-seven ESRD diabetic patients
Abbreviations are: HD, hemodialysis; [CP], C-peptide concentration; [glu-
(48% males) were studied: 75 (59.1%) African Ameri- cose], glucose concentration; BMI, body mass index.
a Based on clinical criteria defined in the Methods sectioncans (AA), 46 (36.2%) Caucasians (CA), and 6 (4.7%)
Hispanics (H). Age, age at diabetes onset, diabetes dura-
tion, and mean C-peptide concentrations are presented
in Table 2. Demographic parameters (age and gender
P , 0.001). Twenty-six patients could not be categorizeddistribution) or diabetes profile (diabetes duration, age
as type 1 or type 2 diabetics. Of these, 10 patients wereat diagnosis, C-peptide levels, diabetes treatment, and
treated only with insulin (for a mean period of 24.1 6body mass index) were similar in the three ethnic groups
8.2 years; minimum period of treatment was 9 years),(data not shown). Diabetic ESRD patients (N 5 79,
but had onset of diabetes between 30 and 38 years of62.2%) treated with insulin at the time of the study were
age. The remaining 16 patients, who could not be classi-significantly more obese, had less optimally controlled
fied using clinical information, were treated initially withserum glucose, and had lower C-peptide levels as com-
oral hypoglycemic agents, but had an onset of diabetespared with those (N 5 48) treated by only diet and/or
before 35 years of age (8 patients were 30 or youngeroral hypoglycemic agents (Table 3).
at diagnosis) and required insulin therapy within two
years after initial diagnosis. None of these 26 patientsClassification of ESRD diabetic patients according to
clinical criteria had a history of DKA. Clinical phenotyping results are
summarized in Table 4.Using clinical phenotyping criteria (Methods section),
we could categorize only 101 (79.5%) of the 127 ESRD
Classification of ESRD diabetic patients using serumdiabetic patients: 13 were type 1 (10.2%) and 88 were
C-peptide levelstype 2 (69.3%) diabetics. Type 1 and type 2 diabetic
C-peptide concentrations for the study population areESRD patients had similar demographic profiles [age,
presented in Table 2. As shown in Figure 2, contempora-ethnic distribution, and gender distribution (data not
neous C peptide and glucose concentrations failed toshown)], except for diabetes duration (17.9 6 8.7 vs.
29.9 6 5.9 years for type 2 vs. type 1 diabetic, respectively, correlate significantly. In addition, C-peptide levels did
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Table 4. Clinical classification of diabetes phenotypes in 127 diabetic ESRD patients
Standard clinical criteriaa
Unclassifiable diabetes type (N 5 26)
Type 1 (N 5 13) Revised clinical criteriab Type 2 (N 5 88)
Insulin as only treatment Insulin initiated 1 to 2 years after DM
(N 5 10) onset (N 5 16)
Age at onset Age at onset
,35 (N 5 4) $35 (N 5 6) #30 (N 5 9) .30 (N 5 7)
Certain type Consistent with Unclassifiable DM Consistent with Certain type
1 DM type 1 DM type 2 DM 2 DM
Type 1 DM (N 5 17) MODY or Early onset type 2 (N 5 15) Type 2 DM (N 5 95)
Abbreviations are: DM, diabetes mellitus; ESRD, end stage renal disease; MODY, maturity onset diabetes of the young (monogenic diabetes).
a See Methods for details
b Less stringent clinical parameters that classified diabetic ESRD patients, treated only with insulin and with diabetes onset ,35 years of age, as type 1 diabetics
and those who were 30 to 40 years of age and not treated with insulin use during the first year after diabetes onset, as type 2 diabetics. See Discussion for details.
Comparison of classification of diabetic ESRD
patients using clinical and C-peptide
phenotyping criteria
Classifications of diabetic ESRD patients, using clini-
cal or C-peptide criteria are compared in Table 5. Clinical
and C-peptide–based classifications of diabetes were
concordant in only 70.1% of all cases. Eleven of 122
(9.0%) diabetic ESRD patients with significantly ele-
vated (.0.50 nmol/L) C-peptide levels were type 1 dia-
betics, using standard clinical criteria (age of diabetes
onset ,25 years, treatment only with insulin and/or his-
tory of DKA). Surprisingly, diabetic ESRD patients,
classified as type 1 (N 5 11) or type 2 (N 5 88) using
Fig. 2. Relationship between serum glucose and C-peptide levels in 127 clinical criteria, had nearly identical mean C-peptide con-
diabetic ESRD patients. Scatter plot with each data point representing centrations (3.08 6 1.99 vs. 3.37 6 1.81 nmol/L, respec-
contemporaneous C-peptide and plasma glucose concentrations. The
tively, P 5 NS). Using clinical criteria as the standard,data were subjected to linear regression analysis, with the best fit line
depicted. Statistical significance is defined as P , 0.05; P 5 NS, r 5 sensitivity, specificity, positive, and negative predictive
0.04. values of C-peptide concentrations in classifying diabetic
ESRD patients are presented in Table 6.
C-peptide levels in nondiabetic ESRD patientsnot correlate with the age of diabetes onset, diabetes
Since the kidney is the major site of C-peptide metabo-duration, or body mass indexes (data not shown).
lism and excretion, we determined pre-hemodialysisOf the 127 ESRD diabetic patients in the study, 122
C-peptide concentrations in 30 nondiabetic ESRD pa-had pre-hemodialysis C-peptide levels .0.50 nmol/L.
tients (diabetes excluded by normal HbA1c values, nor-Mean corresponding glucose concentrations were 170.6 6
mal glucose concentrations, and medical history) who107.7 mg/dL, with 44 subjects having a serum glucose
were matched for gender, race, and dialysis durationlevel #120 mg/dL. All 122 patients (group A) were classi-
with the study group population. C-peptide concentra-fied as type 2 diabetics using the algorithm described in the
tions were also assayed in diabetic, first-degree relativesMethods section and in Figure 1. Although three ESRD
with normal serum creatinine levels (N 5 37). Distribu-patients (group B) had pre-hemodialysis C-peptide con-
tions of C-peptide concentrations in diabetic ESRD pa-centrations between 0.20 and 0.50 nmol/L, they were
tients, nondiabetic ESRD patients, and first-degree rela-classified as type 2 diabetics (Fig. 1) since their ages at
tives are shown in Figure 3. C-peptide concentrationsdiabetes onset were 36, 37, and 40 years. The remaining
were similar in diabetic and nondiabetic ESRD patients,two patients (group C) had pre-hemodialysis C-peptide
but were 2.5 to 2.7 times higher compared with diabeticconcentrations ,0.20 nmol/L (0.6 ng/mL) despite con-
siblings with normal renal function. The percentages ofcomitant glucose levels of 278 and 375 mg/dL. These
type 1 and type 2 diabetics, according to clinical criteria,two patients were classified as type 1 diabetics since
were similar in the diabetic ESRD patients and theirstimulated C-peptide concentrations remained ,0.20
nmol/L. first-degree relatives. These data suggest that C-peptide
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Table 5. Comparison between classification of diabetic ESRD patients using algorithms based on clinical and C-peptide concentrations
Group A (N 5 122) Group B (N 5 3) Group C (N 5 2)
C-peptide rangea .0.50 nmol/L 0.20–0.50 nmol/L ,0.20 nmol/L
DM classification Type 2 Type 2 Type 1
by [CP]
DM classification Type 1 Type uncertain Type 2 Type 2 Type uncertain Type 1
by clinical (N 5 11) (N 5 25) (N 5 86) (N 5 2) (N 5 1) (N 5 2)
parameters
CP levels 3.0861.97 3.3561.69 3.3761.81
(mean6SD)
[range] [0.52–6.07] [0.73–6.52] [0.76–8.81] [0.44 and 0.46] [0.34] [0.19 and 0.19]
Abbreviations are: DM, diabetes mellitus; CP, C-peptide concentrations, nmol/L; DCCT, Diabetes Complications Control Trial.
a Study group was stratified using the DCCT study group algorithm (see Methods and Figure 1)
Table 6. Sensitivity, specificity, positive predictive and negative predictive values of different C-peptide derived
algorithms for correct identification of type 2 diabetic ESRD patients
Comparison Se Sp PPV NPV
Classification based on [CP] (see Methods and Figure 1)
1/ vs. accepted clinical criteria (see Methods) 100% 5.1% 70.4% 100%
2/ vs. revised clinical criteriaa 100% 6.3% 76.0% 100%
Pre-HD [CP] .0.50 nmol/L (no age of DM onset criteria is used)
1/ vs. strict clinical criteria for reference 97.7% 7.7% 70.5% 60%
2/ vs. revised clinical criteriaa 97.8% 9.4% 76.2% 60%
New algorithm to identify ESRD patients as type 2 DM:
pre-HD [CP] .0.50 nmol/L and age of DM onset $38 years 87.2% 95.1% 97.4% 78.0%
Abbreviations are: HD, hemodialysis; DM, diabetes mellitus; ESRD, end-stage renal disease; [CP], C-peptide concentration; DCCT, Diabetes Complications
Control Trial; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.
a Legend of Table 3 and Discussion for definition
concentrations poorly reflect pancreatic insulin synthesis However, our data show that C-peptide concentrations
did not improve the power of clinical criteria to classifyonce diabetic patients have ESRD.
diabetic ESRD patients accurately. C-peptide concentra-
tions misclassified as type 2 diabetics a substantial pro-
DISCUSSION portion of ESRD diabetic subjects who were classified as
As part of a study to identify genes that regulate dia- type 1 diabetics when using accepted clinical parameters.
betic nephropathy, the accuracy of clinical and biochemi- When clinical criteria are considered as the standard,
cal phenotyping criteria to classify diabetes was evalu- the specificity of C-peptide concentrations to distinguish
ated in ESRD patients [36]. A precise phenotype is type 1 from type 2 diabetes, using norms derived from
necessary to identify genetic loci [15], but phenotyping diabetics with normal renal function (DCCT study) [2],
criteria for type 1 and type 2 diabetes are not well vali- is only 5% when applied to diabetic ESRD patients.
dated in the ESRD population and are imprecise. For C-peptide levels in type 2 diabetic ESRD patients were
example, patients with diabetes onset from age 25 to 30 indistinguishable from type 1 ESRD diabetics or from
years are not included in any of the published classifica- nondiabetic ESRD individuals. However, the number of
tion schemes, which we used to develop clinical pheno- type 1 diabetics enrolled in this study is small, and a
typing criteria for ESRD patients. Further confounding larger sample size may have improved the power of
classification, a significant proportion of diabetic patients C-peptide concentrations to discriminate type 1 and type
have indeterminate phenotypes with features of both 2 diabetic ESRD patients.
type 1 and type 2 diabetes, and diabetes onset may occur To classify patients with type 1 and type 2 diabetes
at least four to seven years before diagnosis in type 2 better, biochemical assays based on pathogenetic mecha-
diabetics [37]. We found that multiple clinical criteria nisms have been developed to identify an autoimmune
were unable to categorize a significant proportion (21%) response directed against pancreatic b cells, that is, anti-
of a diabetic ESRD population as either type 1 or type islet cell or antiglutamic acid decarboxylase antibodies
2 diabetics. To improve the discriminating power of our [1, 5, 42] or functional insulin secretory deficiency, that
clinical criteria, we added C-peptide concentrations, a is, C-peptide determinations. Several studies have shown
sensitive and specific parameter that distinguishes type that in populations with normal renal function, C-peptide
concentrations discriminate type 1 from type 2 diabetes1 from type 2 diabetic patients [1–3, 21, 25, 29, 31, 38–41].
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(N 5 88, a subset of the UREMIDIAB population [30])
with a single fasting C-peptide measurement using
DCCT study criteria [21]. The positive predictive values
of C-peptide concentrations ,0.20 nmol/L was 100% for
type 1 diabetes and 96% for C-peptide concentrations
.0.20 nmol/L for type 2 diabetes. In contrast to our
results, the concordance between the C-peptide concen-
trations and the clinical classification, using criteria simi-
lar to ours, in the UREMDIAB diabetic ESRD popula-
tion was excellent. Clinical criteria categorized only 4%
of patients with measurable C-peptide concentrations as
type 1 diabetics. Our results may be discrepant for two
reasons. First, the racial composition of study popula-
Fig. 3. Distribution of the pre-hemodialysis C-peptide concentrations tions was dissimilar. Ninety percent of the UREMDIABin the diabetic ESRD study population, their diabetic siblings with
subjects were Caucasians [21] compared with only 39%normal renal function and nondiabetic ESRD patients. 1 5 diabetic
ESRD patients classified as type 1 diabetes based on clinical criteria in our study. Race may be an important variable in esti-
(N 5 13); 2 5 diabetic ESRD patients classified as type 2 diabetes mating the prevalence of type 1 and type 2 diabetes frombased on clinical criteria (N 5 88); 3 5 diabetic ESRD patients who
clinical criteria [29, 41]. To address this possibility, wecould not be classified by the clinical criteria (N 5 26); 4 5 diabetic
patients with normal renal function (control group 1); 5 5 nondiabetic applied clinical criteria (fasting C-peptide limit of $0.3
ESRD patients (control group 2). The clinical classification algorithm nmol/L, age of onset $28.9 years, and body mass indexis described in the Methods section (*P , 0.05).
$31.7) for type 2 diabetes used in a large study popula-
tion (N 5 3694) composed of 80% African Americans
[41]. With re-analysis using these revised criteria, 11.2%
[2, 3, 31] and may be used to select the initial therapy of type 1 diabetic ESRD patients in our study population
[38] and predict future insulin requirements [39]. The remain misclassified by C-peptide concentrations, with
discriminative value of C-peptide concentrations in- little improvement in the concordance between classifi-
creases with diabetes duration. Five years after diagnosis, cations based on clinical criteria and C-peptide concen-
all 610 type 1 diabetics included in the DCCT study had tration stratification. A second difference between the
fasting C-peptide concentrations ,0.20 nmol/L [2]. In UREMDIAB analyses and ours was that individual-
contrast, no impairment of b-cell function was described ized criteria were used to categorize diabetic ESRD pat-
in type 2 subjects, who lack anti-islet cell antibodies [43]. ients in the UREMIDIAB study [21], an approach that
C-peptide concentrations are routinely assayed after may have improved agreement between clinical and
fasting or in a provocative test. Some studies have sug- C-peptide concentration classification schemes. To test
gested that a stimulated value adds little information [31, whether the concordance between the classification
44, 45], but other authors emphasize the importance of schemes would improve with a similar approach, we also
changes in C-peptide levels following stimulation with re-analyzed, using revised clinical parameters, 26 pa-
glucagon or a standardized meal [31, 38, 39]. In contrast tients who could not be classified as either type 1 or type
to most studies, we wished to document ongoing insulin 2 diabetes (Table 4). Patients treated with only insulin
synthesis in diabetic ESRD patients by measuring pre- and with a diabetes onset at ,35 years of age (N 5 4)
hemodialysis C-peptide concentrations. Fasting and stim- were categorized as type 1 diabetics. Patients with age
ulated C-peptide levels were obtained only for clarifi- of onset between 30 and 40 years of age were classified
cation in a few patients (1.5%) with low (,0.5 nmol/L) as type 2 diabetics if insulin therapy was not instituted
C-peptide values and an early age of diabetes onset during the year after diabetes diagnosis (N 5 7). Despite
(Methods section). using these less stringent criteria, 15 diabetic ESRD sub-
Previous studies have classified diabetic phenotypes jects remained unclassified (Table 4), and concordance
within an ESRD population. Cowie et al developed an between the classification algorithms only marginally im-
extensive, four-stage classification based on clinical crite- proved (from 70% to 75%). In addition, the proportion
ria to distinguish between type 1 and type 2 diabetes of type 1 diabetic ESRD subjects misclassified by C-pep-
[29]. Similar to our results, 20% of their study population tide concentration criteria also increased (from 9.0% to
did not fit the clinical criteria for either type 1 or type 12.3%) when the revised clinical criteria were applied.
2 diabetes. Classification was clarified only after the clini- Other studies have assayed C-peptide concentrations
cal data for each individual were scored, and four of in diabetic and nondiabetic patients, with renal insuffi-
six diabetologists agreed. Despite these efforts, 9% of ciency. C-peptide concentrations were elevated approxi-
ESRD patients remained unclassified. mately fourfold in diabetic ESRD patients compared
with diabetics with normal GFR [40, 46], consistent withBenhamou et al classified diabetic ESRD patients
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our observations. C-peptide concentrations also have betic ESRD patients in our study who were classified as
type 1 diabetics using accepted clinical criteria had C-pep-been shown to be elevated in nondiabetic animals [47]
and patients [22, 23] with renal insufficiency. Mean fast- tide values indistinguishable from type 2 diabetics. Accu-
rate classification of diabetic ESRD patients for geneticing C-peptide concentrations in nondiabetic continuous
ambulatory peritoneal dialysis patients have been re- epidemiological studies will require both clinical and bio-
chemical criteria, which would need to be validated inported to be 4.3 nmol/L as a result of increased proinsulin
synthesis stimulated by the peritoneal glucose load [35]. dialysis populations.
Regeur, Faber, and Binder reported that the mean fast-
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